HK Stock Market Move | CHINA SANJIANG (02198) rises more than 7%, institutions optimistic about the acceleration of the turnaround of the chemical industry cycle.
China Sanjiang Chemical (02198) rose over 7%, as of the time of writing, up 7.06% to HKD 3.64, with a trading volume of HKD 39.2025 million.
CHINA SANJIANG (02198) rose more than 7%, up 7.06% to HK$3.64 as of the time of writing, with a turnover of HK$39.20 million.
On the news front, an Industrial research report pointed out that the chemical industry in 2026 will usher in a dual opportunity of cyclical recovery and industrial upgrading. The chemical industry has been operating in the bottom range for three years, with the growth rate of construction projects in the industry continuously declining and new production capacity nearing completion. Looking ahead to 2026, in the first year of the "14th Five-Year Plan," domestic stability growth policies are expected to be exerted, the Fed has entered a rate-cut cycle, traditional demand for chemical products is expected to moderately recover; with the push of the "anti-internal jamming" wave, the turning point in the cycle is expected to accelerate, and core chemical assets with global competitive advantage are expected to see profit and valuation recovery.
Public information shows that CHINA SANJIANG is an investment holding company mainly engaged in the production and supply of ethylene oxide, ethylene glycol, polypropylene, and surfactants. The company's main products include ethylene oxide, ethylene glycol, polypropylene (PP), surfactants and water reducers, methyl tertiary butyl ether/carbon four (MTBE/C4), and crude pentene, among other products.
Related Articles

Beijing Huafeng Test & Control Technology's (688200.SH) Chief Financial Officer, Huang Ying, plans to reduce their holdings by no more than 2879 shares.

Zhihu-W (02390) spent $113,500 to repurchase 99,000 shares on January 7th.

Zhejiang Xianju Pharmaceutical(002332.SZ): Dexamethasone sodium phosphate injection approved for registration.
Beijing Huafeng Test & Control Technology's (688200.SH) Chief Financial Officer, Huang Ying, plans to reduce their holdings by no more than 2879 shares.

Zhihu-W (02390) spent $113,500 to repurchase 99,000 shares on January 7th.

Zhejiang Xianju Pharmaceutical(002332.SZ): Dexamethasone sodium phosphate injection approved for registration.

RECOMMEND

Bank Of America Sees Three Drivers Supporting Chinese Consumer Stocks: Low Base, Deep Undervaluation, And Convertible‑Like Defensive Traits
07/01/2026

Cross‑Border E‑Commerce In 2025: Tariffs, Trade Wars, And Shifting Away From The United States
07/01/2026

Asian Stock Markets Record The Strongest Annual Start Ever As Shanghai Composite Hits Multi‑Year High And Sets Longest Winning Streak; Japan And Korea Rally
07/01/2026


